MaxCyte (NASDAQ:MXCT – Get Rating) and Inotiv (NASDAQ:NOTV – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Profitability This table compares MaxCyte and Inotiv’s net margins, return on […]
MaxCyte (NASDAQ:MXCT – Get Rating) and ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares MaxCyte and ProMIS Neurosciences’ net margins, […]
MaxCyte (NASDAQ:MXCT – Get Rating) issued its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05), MarketWatch Earnings reports. MaxCyte had a negative net margin of 52.27% and a negative return on equity of 14.74%. Shares of MXCT opened at […]
GAITHERSBURG, Md., March 22, 2022 /PRNewswire/ MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies
MaxCyte, Inc. (LON:MXCT – Get Rating)’s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 490.79 ($6.38) and traded as low as GBX 401 ($5.21). MaxCyte shares last traded at GBX 410 ($5.33), with a volume of 70,777 shares. The […]